Blueprint Medicines (United States)

Predicting the clinical course of advanced systemic mastocytosis on treatment with avapritinib or midostaurin

Abstract Advanced systemic mastocytosis (AdvSM) is driven by KIT D816V in approximately 95% of cases. Accurate assessment and prediction of clinical course and disease outcome before and during treatment with the KIT inhibitors midostaurin and avapritinib may facilitate optimizat...